Research programme: sordarin antifungals - Diversa

Drug Profile

Research programme: sordarin antifungals - Diversa

Alternative Names: DVSA 103; DVSA 105; DVSA 106; DVSA 107; DVSA 108; DVSA 109

Latest Information Update: 14 May 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer Diversa
  • Class Indenes
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mycoses

Most Recent Events

  • 31 Jan 2006 Discontinued - Preclinical for Mycoses in USA (unspecified route)
  • 15 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Mycoses antimicrobial activity section ,
  • 01 Mar 2004 Diversa's sordarins research programme is available for partnering in Asia (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top